Verve Therapeutics, Inc. (VERV) Financials
VERV Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 752.7 million | 153.2 million |
2023-09-30 | 612.4 million | 152.0 million |
2023-06-30 | 589.1 million | 123.9 million |
2023-03-31 | 634.4 million | 124.9 million |
VERV Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -42.9 million | 9.3 million |
2023-09-30 | -12.9 million | 8.8 million |
2023-06-30 | -50.6 million | 9.0 million |
2023-03-31 | -52.5 million | 8.0 million |
VERV Net Income
No data available :(
VERV Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 624.0 million | - | 74.9 million |
2023-09-30 | 485.2 million | - | 76.8 million |
2023-06-30 | 462.5 million | - | 77.9 million |
2023-03-31 | 508.7 million | - | 80.1 million |
VERV Shares Outstanding
VERV Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 2.2 million | 46.8 million | 12.3 million | - |
2023-09-30 | 1.1 million | 43.8 million | 11.7 million | - |
2023-06-30 | 2.7 million | 47.3 million | 13.4 million | - |
2023-03-31 | 3.4 million | 47.1 million | 12.6 million | - |
VERV Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 5.1 million | 1.5 million |
2023-09-30 | 3.1 million | 3.2 million |
2023-06-30 | 2.1 million | 3.0 million |
2023-03-31 | 1.4 million | 2.8 million |
VERV
Price: $6
52 week price:
Earnings Per Share: -3.12 USD
P/E Ratio: -4.03
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 434163
Market Capitalization: 731.7 million